SCHEMBL1004764

SCHEMBL1004764

COC(=O)c1ccc(C=O)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.53
GLA P06280 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 3/20 0.44
CYP1A2 P05177 1/20 0.42
RAB9A P51151 2/20 0.40
XDH P47989 1/20 0.38
MAPK1 P28482 1/20 0.38
NR4A2 P43354 1/20 0.38
POLB P06746 2/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.36
MMP2 P08253 1/20 0.36
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA7 P43166 2/20 0.35
CA9 Q16790 2/20 0.35
CA14 Q9ULX7 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7497480 0.83 GAA (0.51) GAAGLAKDM4EALDH1A1CYP1A2
SCHEMBL70624 0.81 GAA (0.67) GAAGLAKDM4EALDH1A1CYP1A2
SCHEMBL14078157 0.80 GAA (0.49) GAAGLAKDM4EALDH1A1CYP1A2
SCHEMBL359688 0.80 SMN1; SMN2 (0.47) GAAGLAKDM4EALDH1A1RAB9A
SCHEMBL20594680 0.80 HIF1A (0.36) GAAGLAKDM4EALDH1A1LMNA
SCHEMBL4566358 0.79 KDM4E (0.47) GAAGLAKDM4EALDH1A1CYP1A2
SCHEMBL645360 0.75 KDM4E (0.41) KDM4EALDH1A1LMNAHIF1AEPAS1
SCHEMBL1422945 0.74 KDM4E (0.58) GAAGLAKDM4EALDH1A1CYP1A2
SCHEMBL13804463 0.74 GAA (0.58) GAAGLAKDM4EALDH1A1CYP1A2
SCHEMBL3551459 0.74 GAA (0.58) GAAGLAKDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4582427-A1 USP1 INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2025-07-09 EP disclosed
EP-4526298-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS F. Hoffmann-La Roche AG (CH) 2025-03-26 EP disclosed
US-20250074913-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS HOFFMANN-LA ROCHE INC. (US) 2025-03-06 US disclosed
CN-119497713-A USP1 inhibitors 上海齐鲁制药研究中心有限公司 2025-02-21 CN disclosed
CN-119212989-A Pyrazole derivatives as STING agonists 豪夫迈·罗氏有限公司 2024-12-27 CN disclosed
WO-2024155555-A1 NEUROPROTECTIVE COMPOUNDS FOR THERAPEUTIC USE NIMML INSTITUTE (US) 2024-07-25 WO disclosed
WO-2024046471-A9 USP1 INHIBITOR 上海齐鲁制药研究中心有限公司 2024-05-02 WO disclosed
WO-2024046471-A1 USP1 INHIBITOR 上海齐鲁制药研究中心有限公司 2024-03-07 WO disclosed
WO-2023222644-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2023-11-23 WO disclosed
WO-2023222644-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2023-11-23 WO disclosed
EP-0904271-A4 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES UNIV PRINCETON (US) 2002-01-23 EP disclosed
EP-0904271-A1 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1999-03-31 EP disclosed
US-5849693-A Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIb/IIIa THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-12-15 US disclosed
US-5773411-A CARDIOVASCULAR DISORDERS AND BRAIN DISORDERS AND COAGULANTS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-30 US disclosed
US-5691329-A Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-11-25 US disclosed
WO-1997041115-A1 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1997-11-06 WO disclosed
US-5563158-A CARDIOVASCULAR DISORDERS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-10-08 US disclosed
EP-0672059-A1 CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-09-20 EP disclosed
WO-1995018111-A1 COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-07-06 WO disclosed
WO-1994011398-A1 CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074913-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS STING1, CGAS, MAVS GAA 3157/4885GLA 3263/4885KDM4E 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.